Companion diagnostics continue to be all the rage. This time, Response Genetics is drawing increased attention from GlaxoSmithKline ($GSK). The drug giant already works with Response, which conducts companion diagnostic tests and other tasks for GSK's immunotherapy and cancer pipeline drug candidates, ShareCast reports. But now GSK has boosted its stake in Response, acquiring 5 million newly issued shares in the company. Story